Albert Sabin a vaccine to prevent or mitigate the illness. The Sabin vaccine is an oral vaccine containing weakened forms of strains of polio viruses. In 1955, Salk's "killed" vaccine was released for use. It was effective in preventing most of the complications of polio, but did not prevent the initial intestinal infection. The Sabin vaccine is easier to give than the earlier vaccine developed by Salk in 1954, and its effects last longer. Sabin first tested his live attenuated oral vaccine at the Chillicothe Ohio Reformatory in late 1954. From 1956–1960, he worked with Russian colleagues to perfect the oral vaccine
Sabin Vaccine Institute Development, the Global Network for Neglected Tropical Diseases, and Vaccine Advocacy and Education. Through its Product Development Partnership (PDP), Sabin has worked with organizations such as King Saud University, Texas Children's Hospital Center, International Vaccine Institute, and George Washington University School of Medicine & Health Sciences toward its goals, with funding and support from the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases, the Dutch Ministry of Foreign Affairs, the Brazilian Ministry of Health and other benefactors. In 2012, Sabin partnered with International Vaccine Institute to combine their research, development, and promotion efforts in Asia,